Investigators from CMR Curediab Metabolic Research GmbH recently disclosed preclinical data for a novel hepatoprotective thioacrylamide compound, HK-3, being developed for the treatment of metabolic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results